PriceTargets.com logo

Kyntra Bio - KYNB Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$6.93 As of 02/27/2026 05:00 PM ET
▼ -0.04 (-0.57%)

This chart shows the closing price for KYNB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kyntra Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KYNB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KYNB

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Kyntra Bio in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $6.93.

This chart shows the closing price for KYNB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in Kyntra Bio. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/31/2026
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/2/2026

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/27/2026HC WainwrightUpgradeStrong-Buy
2/6/2026Zacks ResearchDowngradeStrong-Buy ➝ Hold
1/14/2026Weiss RatingsInitiated CoverageSell (D+)
1/8/2026Zacks ResearchUpgradeHold ➝ Strong-Buy
(Data available from 3/2/2021 forward)

News Sentiment Rating

-0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/3/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/2/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/2/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/1/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/1/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/31/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/30/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/1/2026

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Kyntra Bio logo
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $6.93
Low: $6.81
High: $7.06

50 Day Range

MA: N/A

52 Week Range

Now: $6.93
Low: $4.85
High: $12.60

Volume

43,976 shs

Average Volume

41,481 shs

Market Capitalization

$28.07 million

P/E Ratio

0.13

Dividend Yield

N/A

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of Kyntra Bio?

The following sell-side analysts have issued stock ratings on Kyntra Bio in the last twelve months: HC Wainwright, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for KYNB.

What is the current price target for Kyntra Bio?

0 Wall Street analysts have set twelve-month price targets for Kyntra Bio in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Kyntra Bio in the next year.
View the latest price targets for KYNB.

What is the current consensus analyst rating for Kyntra Bio?

Kyntra Bio currently has 1 sell rating, 1 hold rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in KYNB, but not buy more shares or sell existing shares.
View the latest ratings for KYNB.

What other companies compete with Kyntra Bio?

Other companies that are similar to Kyntra Bio include Ovid Therapeutics, Cardiol Therapeutics, Korro Bio, Repare Therapeutics and Genelux. Learn More about companies similar to Kyntra Bio.

How do I contact Kyntra Bio's investor relations team?

Kyntra Bio's physical mailing address is 409 ILLINOIS STREET, SAN FRANCISCO, CA, 94158. The company's listed phone number is (415) 978-1200 and its investor relations email address is [email protected]. The official website for Kyntra Bio is fibrogen.com. Learn More about contacing Kyntra Bio investor relations.